Log in

NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

$19.58
-1.65 (-7.77 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$19.50
Now: $19.58
$21.05
50-Day Range
$14.38
MA: $18.56
$27.72
52-Week Range
$4.26
Now: $19.58
$29.61
Volume1.20 million shs
Average Volume3.03 million shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Read More
Karyopharm Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.89 million
Book Value$0.79 per share

Profitability

Net Income$-199,590,000.00
Net Margins-488.08%

Miscellaneous

Employees332
Market Cap$1.28 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.


Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

How has Karyopharm Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KPTI shares have decreased by 7.8% and is now trading at $19.58. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Karyopharm Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Karyopharm Therapeutics.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Karyopharm Therapeutics.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its quarterly earnings results on Thursday, February, 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.10. The company earned $18.10 million during the quarter, compared to analyst estimates of $16.48 million. Karyopharm Therapeutics had a negative return on equity of 254.74% and a negative net margin of 488.08%. View Karyopharm Therapeutics' earnings history.

What price target have analysts set for KPTI?

8 brokerages have issued 1-year price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $25.00 to $43.00. On average, they expect Karyopharm Therapeutics' stock price to reach $30.71 in the next year. This suggests a possible upside of 56.9% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics.

Has Karyopharm Therapeutics been receiving favorable news coverage?

Media coverage about KPTI stock has trended very positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutKaryopharm Therapeutics.

Are investors shorting Karyopharm Therapeutics?

Karyopharm Therapeutics saw a increase in short interest in the month of February. As of February 14th, there was short interest totaling 12,930,000 shares, an increase of 34.4% from the January 30th total of 9,620,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 11.1 days. Currently, 24.2% of the shares of the company are sold short. View Karyopharm Therapeutics' Current Options Chain.

Who are some of Karyopharm Therapeutics' key competitors?

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Amarin (AMRN), Exelixis (EXEL), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
  • Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
  • Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
  • Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Palo Alto Investors LP (7.32%), State Street Corp (5.14%), Delphi Management Partners VIII L.L.C. (3.60%), Candriam Luxembourg S.C.A. (1.35%), Geode Capital Management LLC (1.32%) and FMR LLC (1.01%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View institutional ownership trends for Karyopharm Therapeutics.

Which institutional investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, J. Goldman & Co LP, Palo Alto Investors LP, Candriam Luxembourg S.C.A., Schonfeld Strategic Advisors LLC, UBS Group AG, and FMR LLC. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, and Sharon Shacham. View insider buying and selling activity for Karyopharm Therapeutics.

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was acquired by a variety of institutional investors in the last quarter, including Delphi Management Partners VIII L.L.C., Parkman Healthcare Partners LLC, Fairmount Funds Management LLC, Marshall Wace LLP, EAM Investors LLC, Renaissance Technologies LLC, California Public Employees Retirement System, and EAM Global Investors LLC. View insider buying and selling activity for Karyopharm Therapeutics.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $19.58.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $1.28 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe. View additional information about Karyopharm Therapeutics.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]


MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  469 (Vote Outperform)
Underperform Votes:  308 (Vote Underperform)
Total Votes:  777
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel